Interventions: The intervention comprises of single time-point pharmacogenetics screening for: 1. DPYD gene test for patients newly commencing on 5-fluorouracil and capecitabine chemotherapy 2. UGT1

NIAID Data Ecosystem40

Additional file 3 of Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer

肿瘤精准治疗

组合预测

Additional file 3. Tables S1-S8.

NIAID Data Ecosystem30

Additional file 7: of Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas

肿瘤精准治疗

表观遗传生物标志物

Table S4. Univariate and multivariate Cox regression analyses in non-G-CIMP/IDH1R132H wt GBMs with RT alone. (XLSX 25 kb)

Figshare2024-02-15 更新50

Known actionable driver oncogene mutations were excluded from neoadjuvant chemoimmunotherapy of non-small cell lung cancer.

肿瘤精准治疗

突变体筛选

Cases G enes M utation sites Case 1 EGFR Exon 19 DeletionsCase 2 EGFR Exon 19 DeletionsCase 3 EGFR Exon 19 DeletionsCase 4 EGFR Exon 21 (L868R) MutationsCase 5 E

Figshare2024-02-03 更新30

Summary of how ctDNA testing impacted clinical management.

资源简介：

相关数据集